The Development and Purposes of Arsenic Detoxification Technology

  • Hiroshi YamauchiEmail author
  • Ayako Takata
  • Yang Cao
  • Koichiro Nakamura
Part of the Current Topics in Environmental Health and Preventive Medicine book series (CTEHPM)


Currently, factors that adversely impact human health all too frequently exist within various industrial settings and in the natural environment, and the continued diversification of industrial activities further exacerbates these health risks. As there is no definitive cure for chronic arsenic poisoning, it is paramount to take prophylactic measures to minimize the chance of accidental inorganic arsenic (iAs) exposure. To that end, we have been attempting to develop detoxification techniques for neutralizing iAs at its sources by focusing on a mechanism for the stimulation of the biosynthesis of methylated arsenic compounds from iAs, a process that naturally occurs in some marine ecosystems. Arsenobetaine (AB) was chosen as a candidate for a detoxified iAs derivative based on its toxicological profile as it is much less toxic than iAs. The detoxification of iAs was verified with arsenical chemical weapons (abandoned stockpiled chemical weapons containing arsenic) and arsenic-contaminated well water. The photocatalytic titanium dioxide system was shown to convert other non-iAs compounds to AB. However, further development of efficiency and economy is considered needed to reach a level of the practical use for any system, and the disposal of arsenic waste generated is still an issue. For the future of humankind, we believe that it is a critical endeavor to further refine the concept and practice of iAs detoxification to minimize iAs-related health impact.


Arsenic Detoxication Arsenical chemical weapons Arsenic-contaminated water Chronic arsenic poisoning 



This work was supported by the JSPS KAKENHI Grant Number JP23406003 to H.Y. and Environment Research and Technology Development Fund (k2334) of the Ministry of the Environment, Japan, to K.N.


  1. 1.
    ATSDR. Toxicological profile for arsenic. Agency for Toxic Substances and Disease Registry. 2007.
  2. 2.
    Yamauchi H, Aminaka Y, Yoshida K, Sun G, Pi J. Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxydeoxyguanine. Waalkes MP. Toxicol Appl Pharmacol. 2004;198(3):291–6.CrossRefGoogle Scholar
  3. 3.
    IARC (International Agency for Research on Cancer). IARC monographs on the evaluation of the carcinogenic risks to humans, suppl. 7. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. Arsenic and arsenic compounds, 100–106, Lyon. 1987.Google Scholar
  4. 4.
    WHO. Arsenic. World Health Organization, updated Nov 2017.
  5. 5.
    UNICEF. Bangladesh 2012–13 MICS final report, 2015.
  6. 6.
    European Commission. Restriction of the use of certain hazardous substances in electrical and electronic equipment(RoHS). Directive 2011/65/EU 2011.
  7. 7.
    Yoshimura Y, Endo Y, Shimoda Y, Yamanaka K, Endo G. Acute arsine poisoning confirmed by speciation analysis of arsenic compounds in the plasma and urine by HPLC-ICP-MS. J Occup Health. 2011;53(1):45–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Conner EA, Yamauchi H, Fowler BA, Akkerman M. Biological indicators for monitoring exposure/toxicity from III–V semiconductors. J Expo Anal Environ Epidemiol. 1993;3(4):431–40.PubMedGoogle Scholar
  9. 9.
    Conner EA, Yamauchi H, Fowler BA. Alterations in the heme biosynthetic pathway from the III–V semiconductor metal, indium arsenide (InAs). Chem Biol Interact. 1995;96(3):273–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Fowler BA, Conner EA, Yamauchi H. Metabolomic and proteomic biomarkers for III-V semiconductors: chemical-specific porphyrinurias and proteinurias. Toxicol Appl Pharmacol. 2005;206(2):121–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Omura M, Hirata M, Tanaka A, Zhao M, Makita Y, Inoue N, Gotoh K, Ishinishi N. Testicular toxicity evaluation of arsenic-containing binary compound semiconductors, gallium arsenide and indium arsenide, in hamsters. Toxicol Lett. 1996;89(2):123–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshida T, Yamauchi H, Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol. 2004;198(3):243–52.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, Hopenhayn-Rich C, Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect. 2002;110(4):331–6.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    WHO. Guidelines for drinking-water quality. 4th Edition. World Health Organization, Geneva. 2011.
  15. 15.
    U.S. EPA. Reregistration eligibility decision for chromated arsenicals. EPA 739-R-08–006. 2008.
  16. 16.
    WPSC. The safety of chromated copper arsenate (CCA)-treated wood. Wood Preservative Science Council. 2008.
  17. 17.
    U.S. EPA. Revised re-registration eligibility decision for MSMA, DSMA, CAMA and Cacodylic Acid. EPA-HQ-OPP-2006-0201. 2006.
  18. 18.
    U.S. EPA. Science issue paper: mode of carcinogenic action for cacodylic acid (dimethylarsinic acid, DMAV) and recommendations for dose response extrapolation. 2005.
  19. 19.
    Webb E, Moon J, Dyrszka L, Rodriguez B, Cox C, Patisaul H, Bushkin S, London E. Neurodevelopmental and neurological effects of chemicals associated with unconventional oil and natural gas operations and their potential effects on infants and children. Rev Environ Health. 2017. doi: Scholar
  20. 20.
    Webb E, Bushkin-Bedient S, Cheng A, Kassotis CD, Balise V, Nagel SC. Developmental and reproductive effects of chemicals associated with unconventional oil and natural gas operations. Rev Environ Health. 2014;29(4):307–18. Scholar
  21. 21.
    Chen CS, Yuan TH, Shie RH, Wu KY, Chan CC. Linking sources to early effects by profiling urine metabolome of residents living near oil refineries and coal-fired power plants. Environ Int. 2017;102:87–96. Scholar
  22. 22.
    Yuan TH, Chio CP, Shie RH, Pien WH, Chan CC. The distance-to-source trend in vanadium and arsenic exposures for residents living near a petrochemical complex. J Expo Sci Environ Epidemiol. 2016;26(3):270–6. Scholar
  23. 23.
    Minichilli F, Nuvolone D, Bustaffa E, Cipriani F, Vigotti MA, Bianchi F. State of health of populations residing in geothermal areas of Tuscany. Epidemiol Prev. 2012;36(5 Suppl 1):1–104.PubMedGoogle Scholar
  24. 24.
    Abandoned Chemical Weapons Office, Cabinet Office, Government of Japan. Abandoned chemical weapons (ACW) projects in China.
  25. 25.
    Inada Y, Kurose K, Washida T. Destruction of old chemical bombs using DAVINCH™ at Kanda, Japan. Global demilitarization symposium & exhibition. 2007.
  26. 26.
    Dundee Sustainable Technologies Inc. Method for stabilization of arsenic. United States patent application 20170291828, A1. 2017.
  27. 27.
    Carlin DJ, Naujokas MF, Bradham KD, Cowden J, Heacock M, Henry HF, Lee JS, Thomas DJ, Thompson C, Tokar EJ, Waalkes MP, Birnbaum LS, Suk WA. Arsenic and environmental health: state of the science and future research opportunities. Environ Health Perspect. 2016;124(7):890–9. Scholar
  28. 28.
    Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ. Arsenic exposure and toxicology: a historical perspective. Toxicol Sci. 2011;123(2):305–32. Scholar
  29. 29.
    Edmonds JS, Francesconi KA, Cannon JR, Raston CL, Skelton BW, White AH. Isolation, crystal structure and synthesis of arsenobetaine, the arsenical constituent of the western rock lobster Panulirus longipes cygnus George. Tetrahedron Lett. 1977;18(18):1543–6.CrossRefGoogle Scholar
  30. 30.
    Yamauchi H, Yamamura Y. Metabolism and excretion of orally ingested trimethylarsenic in man. Bull Environ Contam Toxicol. 1984;32(6):682–7.CrossRefGoogle Scholar
  31. 31.
    Francesconi KA, Edmonds JS. The identification of arsenobetaine as the sole water-soluble arsenic constituent of the tail muscle of the western king prawn Penaeus latisulcatus. Comp Biochem Physiol C. 1987;87(2):345–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Shibata Y, Morita M. Characterization of organic arsenic compounds in bivalves. Appl Organomet Chem. 1992;6:343–9.CrossRefGoogle Scholar
  33. 33.
    Vahter M, Marafante E, Dencker L. Metabolism of arsenobetaine in mice, rats and rabbits. Sci Total Environ. 1983;30:197–211.CrossRefGoogle Scholar
  34. 34.
    Yamauchi H, Kaise T, Yamamura Y. Metabolism and excretion of orally administered arsenobetaine in the hamster. Bull Environ Contam Toxicol. 1986;36(3):350–5.CrossRefGoogle Scholar
  35. 35.
    Kaise T, Fukui S. The chemical form and acute toxicity of arsenic compounds in marine organisms. Appl Organometal Chem. 1992;6:155–60. Scholar
  36. 36.
    Yamauchi H, Takahashi K, Yamamura Y, Kaise T. Metabolism and excretion of orally and intraperitoneally administered trimethylarsine oxide in the hamster. Toxicol Environ Chem. 1989;22:69–76. Scholar
  37. 37.
    Kaise T, Watanabe S, Itoh K. The acute toxicity of arsenobetaine. Chemosphere. 1985;14(9):1327–32.CrossRefGoogle Scholar
  38. 38.
    Nakamura K, Hisaeda Y, Pan L, Yamauchi H. Detoxification system for inorganic arsenic: transformation of As2O3 into TMAO by vitamin B12 derivatives and conversion of TMAO into arsenobetaine. Chem Commun. 2008;41:5122–4.CrossRefGoogle Scholar
  39. 39.
    Nakamura K, Hisaeda Y, Pan L, Yamauchi H. Methyl transfer from a hydrophobic vitamin B12 derivative to arsenic trioxide. J Organomet Chem. 2009;694:916–21.CrossRefGoogle Scholar
  40. 40.
    Nakamura K. Biomimetic and bio-inspired catalytic system for arsenic detoxification: bio-inspired catalysts with vitamin-B12 cofactor. London: InTech; 2011. Google Scholar
  41. 41.
    WHO. Developing national strategies for phasing out mercury-containing thermometers and sphygmomanometers in health care, including in the context of the Minamata Convention on Mercury: key considerations and step-by-step guidance. 2015.
  42. 42.
    Robinson RO. Tetraethyl lead poisoning from gasoline sniffing. JAMA. 1978;240(13):1373–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Yamamura Y, Arai F, Yamauchi H. Urinary excretion pattern of triethyllead, diethyllead and inorganic lead in the tetraethyllead poisoning. Ind Health. 1981;19(2):125–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Rahman A, Vahter M, Smith AH, Nermell B, Yunus M, Arifeen SE, Persson LA, Ekstrom EC. Arsenic exposure during pregnancy and size at birth: a prospective cohort study in Bangladesh. Am J Epidemiol. 2009;169(3):304–12. Scholar
  45. 45.
    Hamadani JD, Tofail F, Nermell B, Gardner R, Shiraji S, Bottai M, Arifeen SE, Huda SN, Vahter M. Critical windows of exposure for arsenicassociated impairment of cognitive function in pre-school girls and boys: a population-based cohort study. Int J Epidemiol. 2011;40(6):1593–604. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Hiroshi Yamauchi
    • 1
    Email author
  • Ayako Takata
    • 1
  • Yang Cao
    • 1
  • Koichiro Nakamura
    • 2
  1. 1.Department of Preventive MedicineSt. Marianna University School of MedicineKawasakiJapan
  2. 2.R&D DepartmentNippon Sheet Glass Co. Ltd.TokyoJapan

Personalised recommendations